carbostyril has been researched along with Neoplasms in 130 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (1.54) | 18.7374 |
1990's | 10 (7.69) | 18.2507 |
2000's | 45 (34.62) | 29.6817 |
2010's | 58 (44.62) | 24.3611 |
2020's | 15 (11.54) | 2.80 |
Authors | Studies |
---|---|
Bindu, B; Manikandan, A; Vijayalakshmi, S | 1 |
Anandam, A; Jain, P; Jayshree, BS; Kar, SS; Kumar, N; Rai, A; Raj, VP; Rao, CM; Thomas, S | 1 |
Ambudkar, SV; Chen, ZS; Ji, N; Lei, ZN; Lusvarghi, S; Teng, QX; Wang, JQ; Wu, ZX; Yang, Y | 1 |
Ausekle, E; Ejaz, SA; Iqbal, J; Khan, I; Langer, P; Miliutina, M | 1 |
Chein, RJ; Chen, JJW; Cheng, TR; Chou, TH; Chung, WC; Hong, TM; Lee, TC; Lin, MS; Tsai, ML; Weng, CW; Wong, CH; Yang, PC; Yang, SC | 1 |
Kaiser, J | 1 |
Andrade, CH; Custodio, JMF; D'Oliveira, GDC; Filho, JTM; Junior, PSC; Napolitano, HB; Neves, BJ; Perez, CN; Silveira-Lacerda, EP; Vaz, WF | 1 |
Ashwell, S; Barr, KJ; Campbell, AM; Caravella, JA; Castro, J; Clarke, A; Diebold, RB; Dinsmore, CJ; Ericsson, A; Gotur, D; Gustafson, G; Josephine, HR; Katz, M; Kershaw, M; Lin, J; Lu, W; Toms, AV; Walker, D; Wang, Z; Yao, L | 1 |
Bagal, SK; Bickerton, S; Bodnarchuk, MS; Breed, J; Carbajo, RJ; Cassar, DJ; Chakraborty, A; Cosulich, S; Cumming, I; Davies, M; Eatherton, A; Evans, L; Feron, L; Fillery, S; Gleave, ES; Goldberg, FW; Hanson, L; Harlfinger, S; Howard, M; Howells, R; Jackson, A; Kemmitt, P; Kettle, JG; Kingston, JK; Lamont, S; Lewis, HJ; Li, S; Liu, L; Ogg, D; Phillips, C; Polanski, R; Robb, G; Robinson, D; Ross, S; Smith, JM; Tonge, M; Whiteley, R; Yang, J; Zhang, L; Zhao, X | 1 |
Chen, J; Cheng, Z; Fletcher, M; Jensen, BC; Liu, Y; Xia, P | 1 |
Momo, K; Nio, Y; Sasaki, T; Shimizu, H; Sugita, H | 1 |
Chin, HG; Fitzgerald, K; George, K; Hansen, U; Pedamallu, CS; Roberto, MP; Schaus, SE; Shah, J; Shin, H; Stoiber, P; Willoughby, JLS | 1 |
Asou, H; Doi, T; Funai, T; Inoue, K; Kondo, S; Ranka, VK; Tajimi, M; Wacheck, V | 1 |
Ben Taleb, A; Gözüaçık, D; Ilgar, M; Karakuş, S; Kilislioğlu, A; Kutlu, HM; Kutlu, Ö; Tan, E | 1 |
Ahirrao, P; Bakhle, D; Bernstein, PR; Bhat, T; Bhonde, M; Bommakanti, A; Bora, P; Francis, A; George, KS; Gole, G; Goyal, H; Gundu, J; Gupta, NR; Gupta, R; Hajare, AK; Jadhav, GR; Jagdale, AR; Jana, G; Kale, R; Kamalakannan, P; Kamble, N; Kamboj, RK; Karche, NP; Khanwalkar, H; Khedkar, N; Kukreja, G; Kumar, P; Kumar, R; Kurhade, SP; Limaye, R; Mallurwar, S; Modi, D; Naidu, S; Naik, KR; Narasimham, L; Nemmani, K; Nigade, PB; Pagdala, V; Palle, VP; Patil, V; Pawar, S; Pawar, Y; Phukan, S; Powar, RG; Praveen Kumar, VR; Rao Irlapati, N; Shaikh, JS; Shankar, RB; Sharma, S; Singh, M; Sinha, N; Thube, BR; Tilekar, AR; Volam, H; Wahid, S | 1 |
Chen, Y; Du, T; Han, J; Li, D; Li, G; Li, Z; Liu, M; Liu, Z; Wang, Q; Zhang, N | 1 |
Bardaweel, SK; Hajjo, R; Haroon, RA; Sabbah, DA; Sweidan, K | 1 |
Das, R; Mehta, DK; Sahu, RK; Sharma, D; Sharma, V | 1 |
Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Italiano, A; Massard, C; Merchan, J; Oakley, G; Pant, S; Tap, WD; Yu, D; Yuen, E | 1 |
Merkus, D; Schermuly, RT | 1 |
Bagrel, D; Botta, B; Czepukojc, B; Evain-Bana, E; Jacob, C; Kirsch, G; Mai, A; Meiser, P; Montenarh, M; Mori, M; Patsilinakos, A; Ragno, R; Stazi, G; Valente, S; Xu, Z; Zwergel, C | 1 |
Kukowska, M | 1 |
Callies, S; LaBell, ES; Lee, LB; Satonin, DK; Schmalz, CA; Wickremsinhe, ER | 1 |
Chen, S; Hong, X; Li, LP; Lu, X; Ma, FE; Ni, QL; Pan, YM; Peng, Y; Wu, YM; Yang, JM; Zhang, Y | 1 |
Aboshanab, KMA; Ashour, MS; El-Mahallawy, HA; Elkhatib, WF; Hamed, SM; Helmy, MM | 1 |
Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J | 1 |
Chu, XM; Gong, KK; Liang, LL; Liu, W; Sun, KL; Wang, C; Zhao, CY | 1 |
Ashton, TM; Herbert, KJ; Higgins, GS; Pirovano, G; Prevo, R | 1 |
Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
Chen, D; Murugesan, S; Nadkarni, DH; Qin, JJ; Velu, SE; Wang, H; Wang, MH; Wang, W; Zhang, R | 1 |
Gao, HY; Guan, Y; Jiang, Y; Shi, SP; Tu, PF; Wang, XX; Wu, LJ; Xiao, CL; Zan, K; Zeng, KW | 1 |
Fox, JL | 1 |
Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF | 1 |
Dalgleish, A; Damber, JE; Pili, R; Raymond, E; Smith, M | 1 |
Aleksić, M; Bertoša, B; David-Cordonnier, MH; Depauw, S; Karminski-Zamola, G; Kralj, M; Martin-Kleiner, I; Nhili, R; Tomić, S | 1 |
Hsu, TC; Wu, X; Zheng, YL | 1 |
Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
Arterburn, JB; Hathaway, HJ; Nayak, TK; Norenberg, JP; Prossnitz, ER; Ramesh, C | 1 |
Britten, CD; George, D; Kulkarni, S; Liu, A; Mortimer, J; Quinlan, M; Scott, JW; Sharma, S | 1 |
Atalay, R; Banoglu, E; Çalışkan, B; Cankara Pirol, Ş; Durmaz, I | 1 |
Chen, BJ; Tanaka, Y; Wu, YL; Zhang, W | 1 |
Abécassis, PY; Angouillant-Boniface, O; Bertrand, T; Bjergarde, K; Carry, JC; Clerc, F; Combeau, C; Crocq-Stuerga, V; Delarbre, L; Delorme, C; Doerflinger, G; Filoche-Rommé, B; Gasse, F; Gontier, S; Guizani, H; Krick, A; Lachaud, S; Le Moigne, R; Lebel, R; Ma, N; Maignan, S; Mauger, J; Minoux, H; Monget, S; Monteiro, ML; Murer, M; Nair, A; Nicolas, JP; Parmantier, E; Perron, S; Pouzieux, S; Prévost, C; Schio, L | 1 |
Carta, D; Ferlin, MG | 1 |
Giglione, P; Liguigli, W; Paglino, C; Porta, C | 1 |
George, D; Infante, JR; Liu, A; Quinlan, M; Ramanathan, RK; Scott, JW; Sharma, S; Tan, E | 1 |
Hu, GQ; Liu, YH; Wang, TX; Wei, XL | 1 |
Gadepalli Narasimha, KK; Gopalakrishnan, A; Kalpattu Kuppusami, B; Manogaran, P; Mariyappan, P; Raghavan, S; Venkatraman, G | 1 |
Bisacchi, GS; Hale, MR | 1 |
Check Hayden, E | 1 |
Batalha, PN; Cruz, DC; da Costa Santos Boechat, F; Peña-Cabrera, E; Vieira de Souza, MC | 1 |
Benites, J; Buc Calderon, P; Delgado, V; Muccioli, GG; Sepúlveda, S; Theoduloz, C; Valderrama, JA | 1 |
Becerra, C; Bruce, J; Carlson, G; Chung, V; Goel, S; Infante, J; Kabbinavar, F; Lockhart, AC; Munster, P; Pant, S; Patel, MR; Sarantopoulos, J; Scott, JW; Sharma, S; Tan, E; Tawbi, H; Yang, S | 1 |
Bantu, R; Banu, S; Bollu, R; Jain, N; Manga, V; Nagarapu, L; Polepalli, S; Vangala, R | 1 |
Alfonsi, R; Botta, B; Cacchi, S; Di Marcotullio, L; Fabrizi, G; Faedda, R; Goggiamani, A; Iazzetti, A; Mori, M | 1 |
Cho, SH; James, TD; Jang, JH; Kang, C; Kim, JS; Kim, WR; Sharma, A | 1 |
Algara, T; Aparicio, S; Balasubramanian, S; Bally, MB; Banáth, J; Brenton, JD; Brown, GW; Caldas, C; Cescon, D; Chiu, DS; Di Antonio, M; Garcia, J; Hieter, P; Ho, B; Kabeer, F; Lai, D; Le, DD; Lin, SC; Mak, TW; Mathew, V; McKinney, S; O'Neil, NJ; Osako, T; Santos, ND; Saunders, DN; Shah, SP; Silvester, J; Soong, J; Soriano, P; Stirling, PC; Thu, K; Tsai, AH; Wei, V; Wong, J; Xian, J; Xu, H; Yap, D; Ye, FB; Zhang, A | 1 |
Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
Chen, XG; Chern, JW; Guo, QL; He, XG; Huang, CH; Li, TK; Li, ZY; Wang, XJ; Yang, Q; You, QD | 1 |
Anderes, K; Bliesath, J; Drygin, D; Ho, CB; Lim, JK; Lin, A; O'Brien, S; Proffitt, C; Rice, WG; Schwaebe, M; Siddiqui-Jain, A; Trent, K; Von Hoff, D; Whitten, JP | 1 |
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L | 1 |
Adelman, DC; Advani, RH; Allen, RS; Berman, CJ; Ebbinghaus, SW; Fox, JA; Gordon, MS; Havrilla, NA; Hoch, U; Hurwitz, HI; Mendelson, DS; Silverman, JA; Wakelee, HA | 1 |
Gray, NS; Hur, W; Jiang, T; Luesch, H; Mason, DE; Peters, EC; Schultz, PG; Sun, Z; Zhang, DD | 1 |
Ezell, SJ; Gurpinar, E; Li, H; Rayburn, ER; Sommers, CI; Velu, SE; Wang, W; Xu, H; Yang, X; Zhang, R; Zhang, X | 1 |
Chandhasin, C; Kurzrock, R; Tsimberidou, AM | 1 |
Calderon, PB; Valderrama, JA; Vásquez, DR; Verrax, J | 1 |
Boettger, S; Breitbart, W | 1 |
Fukuhara, K; Hayaishi, Y; Katsuragi, K; Kodama, S; Morisya, Y; Nakanishi, C; Terakura, M | 1 |
Fraser, A; Gafter-Gvili, A; Kremer, LC; Lawrie, TA; Leibovici, L; Paul, M; van de Wetering, MD; Vidal, L | 1 |
Huang, X; Li, W; Yang, XW | 1 |
de Souza, MV; Facchinetti, V; Gomes, CR; Vasconcelos, TR | 1 |
Kondratyuk, TP; Luqman, S; Marler, LE; Meena, A; Negi, AS; Pezzuto, JM; Singh, P | 1 |
Anand, S; Beijnen, JH; Dubbelman, AC; Krone, K; Marchetti, S; Schellens, JH; Tan, E; Upthagrove, A | 1 |
Antony, L; Björk, A; Björk, P; Brennen, WN; Dalrymple, SL; Gerber, S; Hammers, H; Isaacs, JT; Kachhap, S; Leanderson, T; Luo, J; Olsson, A; Wissing, M; Xing, L | 1 |
Horton, JK; Wilson, SH | 1 |
Anak, O; Angevin, E; Dugan, M; Escudier, B; Feng, Y; Kay, A; Schran, H; Wang, X; Zhou, W | 1 |
Cheson, BD; Gravell, AE; Wright, JJ; Zerivitz, K | 1 |
Adjei, AA; Dy, GK; Haluska, P | 1 |
Bonginelli, P; Capaccetti, B; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Sarmiento, R | 1 |
De la Fuente, JA; Eguiraun, A; Gutierrez, P; León, J; Lorenzo, M; Montero, JC; Ortiz, JM; Pandiella, A; Pipaón, C | 1 |
Jia, G; Lown, JW; Sharma, SK | 1 |
Nishiyama, M; Tahara, E; Tsuruo, T; Yasui, W | 1 |
Angibaud, P; End, D; Venet, M | 1 |
Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A | 1 |
Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S | 1 |
Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J | 1 |
Frisbee-Hume, S; LeBlanc, B; Rolston, KV; Streeter, H; Vaziri, I | 1 |
Bartkowski, LM; Ferrante, KJ; Kajiji, SM; Langevin, M; Lush, R; Mahany, JJ; Moulder, SL; Noe, DA; Paillet, S; Rocha-Lima, C; Sullivan, DM | 1 |
Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Kawaguchi, T; Lara, PN; Lau, DH; Law, LY; Lenz, HJ; Twardowski, P; Wright, JJ | 1 |
Helbig, G; Hołowiecki, J | 1 |
Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
Kurzrock, R | 1 |
Fraser, A; Gafter-Gvili, A; Kremer, L; Leibovici, L; Paul, M; van de Wetering, M | 1 |
Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S | 1 |
Almyroudis, NG; Segal, BH | 1 |
Boutros, R; Dozier, C; Ducommun, B | 1 |
Mesa, RA | 1 |
Favaudon, V; Fernet, M; Giocanti, N; Godon, C; Mégnin-Chanet, F; Noël, G | 1 |
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
De Porre, P; Hayes, S; Perez-Ruixo, JJ; Piotrovskij, V; Zannikos, P; Zhang, S | 1 |
Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S | 1 |
Awada, A; De Porre, P; Dirix, LY; Francois, M; Fumoleau, P; Piccart-Gebhart, M; Verhaeghe, T; Zannikos, P; Zhang, S | 1 |
Beijnen, JH; Boot, H; Chang, I; Crul, M; De Porre, P; Schellens, JH; Siegel-Lakhai, WS; Zhang, S | 1 |
Chen, YC; Guh, JH; Ho, YF; Huang, YC; Kuo, SC; Lin, TP; Lu, PH; Pan, SL; Teng, CM | 1 |
Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S | 1 |
Abbruzzese, A; Arra, C; Baldi, A; Barbieri, A; Budillon, A; Caraglia, M; D'Alessandro, AM; Marra, M; Meo, G; Rapp, UR; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C | 1 |
Fraser, A; Gafter-Gvili, A; Leibovici, L; Paul, M | 1 |
Chide, OE; Orisakwe, OE | 1 |
Aziz, N; Braendle, E; Butzberger-Zimmerli, P; de Bono, JS; Evans, TR; Fox, JA; Garzon, F; Hardie, M; Heise, C; Jadayel, D; Judson, IR; Louie, S; Marriott, C; Michelson, G; Molife, R; Morrison, R; Sarker, D | 1 |
Decker, EA | 1 |
Alder, J; Burres, N; Chu, DT; Clement, JJ; Jarvis, K; Swiniarski, J | 1 |
Aoun, M; Bourguignon, AM; Daneau, D; Janssen, M; Meunier, F; Van der Auwera, P; Varthalitis, I | 1 |
Brunet, S; Domingo-Albós, A; Martínez, C; Martino, R; Pericas, R; Salazar, R; Solá, C; Sureda, A | 1 |
D'Antonio, D; Di Marzio, A; Fioritoni, G; Lacone, A; Lombardo, M; Pizzigallo, E; Romano, F; Staniscia, T; Violante, B | 1 |
Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
Drlica, K; Zhao, X | 1 |
Barza, M; Engels, EA; Lau, J | 1 |
Blatner, GL; Cheson, BD; Wright, J | 1 |
Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J | 1 |
Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ | 1 |
Gabrilove, JL | 1 |
Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
Norman, P | 1 |
Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ | 1 |
Bodey, GP; Ho, DH; LeBlanc, B; Rolston, KV | 1 |
Bodey, GP; Gooch, G; Ho, DH; LeBlanc, B; Rolston, KV | 2 |
34 review(s) available for carbostyril and Neoplasms
Article | Year |
---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Exploring Quinolone Scaffold: Unravelling the Chemistry of Anticancer Drug Design.
Topics: Antineoplastic Agents; Drug Design; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2022 |
Amino acid or peptide conjugates of acridine/acridone and quinoline/quinolone-containing drugs. A critical examination of their clinical effectiveness within a twenty-year timeframe in antitumor chemotherapy and treatment of infectious diseases.
Topics: Acridines; Acridones; Amino Acids; Animals; Anti-Infective Agents; Antineoplastic Agents; Communicable Diseases; Humans; Neoplasms; Peptides; Quinolines; Quinolones; Treatment Outcome | 2017 |
Quinoline and quinolone dimers and their biological activities: An overview.
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplasms; Quinolines; Quinolones | 2019 |
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Humans; Indolizines; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Quinolones; Quinoxalines; Thiophenes; Treatment Outcome | 2018 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones | 2013 |
Mechanisms of action of tasquinimod on the tumour microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Immune System; Neoplasms; Quinolines; Quinolones; Tumor Microenvironment | 2014 |
Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoxazines; Cell Transformation, Neoplastic; Dimerization; Drug Discovery; G-Quadruplexes; Gene Components; Gene Expression Regulation, Neoplastic; Humans; Indoles; Ligands; Molecular Structure; Neoplasms; Perylene; Proto-Oncogene Proteins c-myc; Quinolines; Quinolones; Ribosomes | 2014 |
An overview on 2-arylquinolin-4(1H)-ones and related structures as tubulin polymerisation inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colchicine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Mitosis; Naphthyridines; Neoplasms; Quinazolinones; Quinolones; Signal Transduction; Structure-Activity Relationship; Tubulin Modulators | 2014 |
A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; DNA Topoisomerases, Type II; Drug Discovery; Humans; Models, Molecular; Neoplasms; Quinolones; Signal Transduction; Topoisomerase II Inhibitors | 2016 |
Quinolones in the Search for New Anticancer Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Quinolones | 2016 |
Farnesyltransferase inhibitors: where are we now?
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms; Quinolones | 2010 |
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Cause of Death; Drug Resistance, Bacterial; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Perspectives on the development of novel potentially active quinolones against tuberculosis and cancer.
Topics: Animals; Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Survival; Drug Design; Drug Discovery; Humans; Mice; Microbial Viability; Mycobacterium tuberculosis; Neoplasms; Quinolones; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2012 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
[Innovative treatment in oncology].
Topics: Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinolones | 2002 |
Novel cyclopropylindole conjugates and dimers: synthesis and anti-cancer evaluation.
Topics: Animals; Cyclopropanes; Dimerization; Drug Evaluation; Humans; Indolequinones; Indoles; Neoplasms; Quinolones | 2001 |
Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Neoplasms; Protein Prenylation; Quinolones; Structure-Activity Relationship | 2003 |
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction | 2004 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination | 2005 |
The when and wheres of CDC25 phosphatases.
Topics: Animals; Benzoquinones; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Humans; Isoenzymes; Models, Biological; Naphthoquinones; Neoplasms; Quinolones; Quinones; Thiazoles | 2006 |
Tipifarnib: farnesyl transferase inhibition at a crossroads.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Treatment Outcome | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Quinolones; Tablets | 2006 |
The anti-cancer effects of quinolone antibiotics?
Topics: Antibiotics, Antineoplastic; Humans; Neoplasms; Quinolones | 2007 |
Structural development, haematological immunological and pharmacological effects of quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Blood Cell Count; Blood Cells; Chemotaxis, Leukocyte; Cytokines; Drug Resistance, Bacterial; Humans; Immunologic Factors; Lipopolysaccharides; Neoplasms; Neutropenia; Patents as Topic; Quinolones; Sepsis; Structure-Activity Relationship | 2007 |
The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants.
Topics: Animals; Antioxidants; Arteriosclerosis; Carnosine; Diet; Humans; Linoleic Acid; Linoleic Acids; Neoplasms; Phenols; PQQ Cofactor; Quinolones | 1995 |
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Topics: Bacteria; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Genes, Bacterial; Neoplasms; Quinolones | 1997 |
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.
Topics: Anti-Infective Agents; Antineoplastic Agents; Fever; Humans; Neoplasms; Neutropenia; Opportunistic Infections; Quinolones; Randomized Controlled Trials as Topic; Risk; Trimethoprim, Sulfamethoxazole Drug Combination | 1998 |
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes.
Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins | 2001 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
Tipifarnib (Janssen Pharmaceutica).
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Ataxia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, Investigational; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Structure-Activity Relationship; Thrombocytopenia; Treatment Outcome | 2002 |
32 trial(s) available for carbostyril and Neoplasms
Article | Year |
---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolones; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases | 2020 |
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Benzimidazoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Quinolones | 2021 |
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution | 2019 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Capsules; Cross-Over Studies; Dietary Fats; Female; Food Analysis; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Quinolones; Therapeutic Equivalency; Treatment Outcome | 2014 |
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Capsules; Cross-Over Studies; Disease-Free Survival; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinolones; Tablets | 2015 |
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capsules; Cross-Over Studies; Demography; Drug Compounding; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinolones; Tablets; Therapeutic Equivalency; Treatment Outcome; Young Adult | 2016 |
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome | 2009 |
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasms; Quinolones; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2010 |
An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delirium; Female; Humans; Inpatients; Male; Middle Aged; Neoplasms; Piperazines; Prospective Studies; Quinolones; Severity of Illness Index; Statistics, Nonparametric | 2011 |
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Chromatography, Liquid; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinolones; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tandem Mass Spectrometry; Tissue Distribution; Young Adult | 2012 |
Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
Topics: Benzimidazoles; Drug Administration Schedule; Female; Humans; Male; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Quinolones; Vascular Endothelial Growth Factor A | 2013 |
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors | 2003 |
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome | 2003 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Quinolones; Tandem Repeat Sequences | 2004 |
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
Topics: Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Area Under Curve; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Inhibitory Concentration 50; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Quinolones; Time Factors | 2004 |
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; California; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Prenylation; Quinolones | 2005 |
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones | 2005 |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones | 2006 |
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Glucuronides; Glycoproteins; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Quinolones; Serum Albumin; Tablets; Treatment Outcome | 2006 |
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Topics: Adult; Aged; Area Under Curve; Farnesyltranstransferase; Female; Humans; Liver; Male; Middle Aged; Models, Statistical; Neoplasms; Neutrophils; Quinolones; Time Factors | 2006 |
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome | 2007 |
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolones; Treatment Outcome | 2008 |
A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.
Topics: 4-Quinolones; Adult; Aged; Anti-Infective Agents; Bacteremia; Drug Resistance, Microbial; Drug Tolerance; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Neoplasms; Pefloxacin; Pneumonia; Prospective Studies; Quinolones; Staphylococcal Infections; Teicoplanin | 1994 |
The impact of rufloxacin given as prophylaxis to patients with cancer on their oral and faecal microflora.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteroides; Colony Count, Microbial; Drug Resistance, Microbial; Enterobacteriaceae; Feces; Female; Fluoroquinolones; Humans; Male; Middle Aged; Mouth; Neoplasms; Pilot Projects; Quinolones; Staphylococcus; Streptococcus | 1996 |
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting | 2000 |
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting | 2001 |
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting | 2002 |
65 other study(ies) available for carbostyril and Neoplasms
Article | Year |
---|---|
Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Cell Proliferation; Drug Discovery; High-Throughput Screening Assays; Humans; Hydroxyquinolines; Molecular Structure; Neoplasms; Quinolines; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Elucidation of structure-activity relationship of 2-quinolone derivatives and exploration of their antitumor potential through Bax-induced apoptotic pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxyquinolines; Mice; Neoplasms; Quinolones | 2012 |
PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Quinolones | 2022 |
Exploration of quinolone and quinoline derivatives as potential anticancer agents.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Drug Screening Assays, Antitumor; HeLa Cells; Humans; K562 Cells; MCF-7 Cells; Neoplasms; Quinolines; Quinolones | 2019 |
4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Proliferation; Colchicine; Drug Resistance, Neoplasm; Humans; Molecular Docking Simulation; Neoplasms; Quinolones; Tubulin; Tubulin Modulators | 2019 |
CRISPR reveals some cancer drugs hit unexpected targets.
Topics: Antineoplastic Agents; CRISPR-Cas Systems; Cyclin-Dependent Kinases; Drug Development; Gene Silencing; Humans; Molecular Targeted Therapy; Neoplasms; Quinolones | 2019 |
Dihydroquinoline derivative as a potential anticancer agent: synthesis, crystal structure, and molecular modeling studies.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Mice; Models, Molecular; Molecular Docking Simulation; Neoplasms; Quinolines; Quinolones; Structure-Activity Relationship; Vero Cells | 2021 |
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Isocitrate Dehydrogenase; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Protein Binding; Pyridines; Quinolines; Quinolones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Drug Design; Humans; Male; Mice, Nude; Molecular Conformation; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolones; Rats, Wistar; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1.
Topics: Animals; Apoptosis; Atrophy; Cardiotoxicity; Cyclin-Dependent Kinase 2; Disease Models, Animal; Doxorubicin; Forkhead Box Protein O1; Gene Expression Regulation; Heart; Humans; Mice; Muscle Proteins; Myocytes, Cardiac; Neoplasms; Quinolones; Signal Transduction; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2020 |
Prophylactic Quinolone Prescription Patterns Related to Febrile Neutropenia in Cancer Chemotherapy Outpatients.
Topics: Febrile Neutropenia; Humans; Neoplasms; Outpatients; Quinolones; Retrospective Studies | 2020 |
Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence.
Topics: Apoptosis; Benzodioxoles; Cell Cycle Checkpoints; Cell Division; Cellular Senescence; Chromosomes, Human; DNA-Binding Proteins; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Intravital Microscopy; Molecular Targeted Therapy; Neoplasms; Quinolones; RNA, Small Interfering; Time-Lapse Imaging; Transcription Factors | 2020 |
Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters.
Topics: Antineoplastic Agents; Drug Carriers; HeLa Cells; Humans; Neoplasms; Polyethylene Glycols; Quinolones; Resins, Plant | 2021 |
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Half-Life; Humans; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Naphthyridines; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Structure-Activity Relationship; Transplantation, Heterologous | 2020 |
Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(iv) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line; DNA; DNA Damage; Histones; Humans; Male; Mice, Inbred BALB C; Mitochondria; Neoplasms; Organoplatinum Compounds; Quinolones; Reactive Oxygen Species; Serum Albumin; Tumor Suppressor Protein p53 | 2021 |
Topics: Amides; Caco-2 Cells; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Molecular Docking Simulation; Neoplasms; Quinolones; Transcription Factors | 2020 |
Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited.
Topics: Humans; Hypertension, Pulmonary; Hypoxia; Neoplasms; Prenylation; Quinolones; rhoB GTP-Binding Protein | 2017 |
Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coumarins; Enzyme Inhibitors; Humans; Neoplasms; Quantitative Structure-Activity Relationship; Quinolones | 2017 |
Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agent.
Topics: Administration, Oral; Antineoplastic Agents; Calibration; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Data Accuracy; Dried Blood Spot Testing; Hematocrit; Humans; Neoplasms; Pyridines; Quinolones; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Coordination Complexes; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Models, Molecular; Neoplasms; Phosphorylation; Quinolones; Rhodium; Xenograft Model Antitumor Assays | 2018 |
Plasmid-Mediated Quinolone Resistance in Gram-Negative Pathogens Isolated from Cancer Patients in Egypt.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Egypt; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Neoplasms; Plasmids; Quinolones | 2018 |
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Proliferation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mammary Glands, Human; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Stability; Pyrroles; Quinolones; Transforming Growth Factor beta2; Ubiquitination; Up-Regulation | 2013 |
Quinolone alkaloids with antibacterial and cytotoxic activities from the fruits of Evodia rutaecarpa.
Topics: Alkaloids; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Evodia; Fruit; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Neoplasms; Phytotherapy; Plant Extracts; Quinolones | 2013 |
FDA moves on breakthrough therapies.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Drug Approval; Neoplasms; Quinolones; Terminal Care; United States | 2013 |
Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties.
Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; DNA; Drug Screening Assays, Antitumor; Humans; Neoplasms; Nitrogen; Quantitative Structure-Activity Relationship; Quinolones; Thiophenes; Topoisomerase II Inhibitors | 2014 |
Mutagen sensitivity as measured by induced chromatid breakage as a marker of cancer risk.
Topics: 4-Nitroquinoline-1-oxide; 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Bleomycin; Cells, Cultured; Chromatids; DNA Breaks, Double-Stranded; Genetic Markers; Genetic Predisposition to Disease; Humans; Lymphocytes; Mutagens; Neoplasms; Quinolones; Radiation Injuries; Risk | 2014 |
GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.
Topics: Animals; Binding, Competitive; Cell Line, Tumor; Diagnostic Imaging; Estrogens; Female; Humans; Immunohistochemistry; Ligands; Mice, Nude; Neoplasms; Ovariectomy; Quinolones; Receptors, Estrogen; Staining and Labeling; Technetium; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carboxylic Acids; Cell Cycle Checkpoints; Cell Proliferation; Drug Screening Assays, Antitumor; Flow Cytometry; G1 Phase; Humans; Molecular Structure; Neoplasms; Pyrazoles; Quinolones; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
SAR156497, an exquisitely selective inhibitor of aurora kinases.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; Benzimidazoles; Female; HCT116 Cells; Humans; Mice, SCID; Models, Chemical; Models, Molecular; Molecular Structure; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinolones; Sf9 Cells; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2015 |
Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
Topics: Benzimidazoles; Clinical Trials as Topic; Humans; Neoplasms; Quinolones; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2015 |
Quinolone-indolone conjugate induces apoptosis by inhibiting the EGFR-STAT3-HK2 pathway in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Hexokinase; Humans; Neoplasms; Quinolones; Signal Transduction; STAT3 Transcription Factor | 2015 |
Synthesis and anticancer activity of novel curcumin-quinolone hybrids.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Curcumin; Humans; Neoplasms; Quinolones; Reactive Oxygen Species | 2015 |
Promising gene therapies pose million-dollar conundrum.
Topics: Aminophenols; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biotechnology; Cystic Fibrosis; Drug Costs; Drug Industry; Genetic Therapy; Humans; Insurance, Health; Neoplasms; Quinolones; Sofosbuvir | 2016 |
Synthesis and Cytotoxic Activity on Human Cancer Cells of Novel Isoquinolinequinone-Amino Acid Derivatives.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Neoplasms; Quinolones | 2016 |
Design, synthesis and docking studies of novel 1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamide derivatives as a potential anti-proliferative agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Docking Simulation; Neoplasms; Piperazines; Quinolones; Tubulin Modulators | 2017 |
Design, Palladium-Catalyzed Synthesis, and Biological Investigation of 2-Substituted 3-Aroylquinolin-4(1H)-ones as Inhibitors of the Hedgehog Signaling Pathway.
Topics: Animals; Antineoplastic Agents; Catalysis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Design; Hedgehog Proteins; Humans; Mice; Models, Molecular; Neoplasms; Palladium; Quinolones; Signal Transduction | 2017 |
Targeted tumor detection: guidelines for developing biotinylated diagnostics.
Topics: 1-Naphthylamine; Biotin; Biotinylation; Fluorescent Dyes; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Microscopy, Confocal; Microscopy, Fluorescence; Naphthalimides; Neoplasms; Optical Imaging; Quinolones | 2017 |
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Topics: Animals; Base Sequence; Benzothiazoles; Benzoxazines; BRCA1 Protein; BRCA2 Protein; Caenorhabditis elegans; Cell Line, Tumor; Chromosomal Instability; DNA Damage; DNA Repair; DNA Replication; DNA, Ribosomal; Female; G-Quadruplexes; Genome, Human; Genotype; Homologous Recombination; Humans; Mice; Naphthyridines; Neoplasms; Quinolones; Saccharomyces cerevisiae; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Discovery; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Naphthyridines; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2009 |
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Topics: Animals; Apoptosis; Benzoxazines; Cell Line, Tumor; Cell Nucleolus; DNA Polymerase I; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Female; G-Quadruplexes; HL-60 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Nucleolin; Phosphoproteins; Quinolones; RNA-Binding Proteins; RNA, Ribosomal; Telomere; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
A small-molecule inducer of the antioxidant response element.
Topics: Antioxidants; Carcinogens; Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasms; NF-E2-Related Factor 2; Protein Binding; Quinolones; Response Elements; Structure-Activity Relationship; Ubiquitination | 2010 |
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Neoplasms; Protein Binding; Pyrroles; Quinolones; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death.
Topics: Adult; Ascorbic Acid; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cytostatic Agents; Female; Humans; L-Lactate Dehydrogenase; Leukocytes; Male; Middle Aged; Necrosis; Neoplasms; Oxidation-Reduction; Oxidative Stress; Poly(ADP-ribose) Polymerases; Quinolones; Reactive Oxygen Species | 2012 |
[The effects of Rebamipide and Polaprezinc mouthwash and uptake on mucositis induced by chemotherapy].
Topics: Aged; Alanine; Antineoplastic Agents; Carnosine; Female; Humans; Male; Middle Aged; Mouthwashes; Mucositis; Neoplasms; Organometallic Compounds; Quality of Life; Quinolones; World Health Organization; Zinc Compounds | 2011 |
New cytotoxic quinolone alkaloids from fruits of Evodia rutaecarpa.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Evodia; Fruit; Hep G2 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Phytotherapy; Plant Extracts; Quinolones | 2012 |
Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Cell Line, Tumor; Flavonoids; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; NAD(P)H Dehydrogenase (Quinone); Neoplasms; NF-kappa B; Quinolones; Tumor Necrosis Factor-alpha | 2012 |
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Topics: Acetylation; Allosteric Regulation; Animals; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Histone Deacetylases; Histones; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Models, Molecular; Neoplasms; Prodrugs; Protein Binding; Protein Structure, Tertiary; Quinolines; Quinolones; Repressor Proteins; RNA Interference; Signal Transduction; Thapsigargin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Predicting enhanced cell killing through PARP inhibition.
Topics: 1-Naphthylamine; Animals; Antineoplastic Agents; Cell Death; DNA Damage; DNA Repair; Enzyme Inhibitors; Humans; Mice; Naphthalimides; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones | 2013 |
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice; Neoplasms; Quinolones; Transplantation, Heterologous | 2002 |
Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells.
Topics: Animals; Anthracenes; Apoptosis; Cell Division; Doxorubicin; Enzyme Activation; Enzyme Inhibitors; HeLa Cells; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; K562 Cells; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Mitogen-Activated Protein Kinases; Models, Chemical; NAD(P)H Dehydrogenase (Quinone); Neoplasms; p38 Mitogen-Activated Protein Kinases; Quinolones; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2002 |
Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; DNA Repair; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Proteins; Neoplasms; Quinolones; Xenograft Model Antitumor Assays | 2003 |
In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
Topics: Anti-Bacterial Agents; Enterococcus; Fermentation; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Neutropenia; Quinolones; Staphylococcus; Streptococcus | 2004 |
Farnesyltransferase inhibitors.
Topics: Acylation; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Middle Aged; Neoplasm Proteins; Neoplasms; Protein Processing, Post-Translational; Quinolones; ras Proteins; Treatment Outcome | 2005 |
Antibacterial prophylaxis in patients with cancer and neutropenia.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Fever; Humans; Neoplasms; Neutropenia; Ofloxacin; Pseudomonas Infections; Quinolones | 2006 |
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis.
Topics: 1-Naphthylamine; Animals; Cricetinae; DNA; DNA Replication; Humans; Mice; Mice, Knockout; Naphthalimides; Neoplasms; Nucleic Acid Synthesis Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones; Radiation Tolerance; Radiation-Sensitizing Agents; S Phase; Tumor Cells, Cultured | 2006 |
Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase; Humans; Neoplasms; Paclitaxel; Quinolones; Tubulin; Tubulin Modulators; Vincristine | 2007 |
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Farnesyltranstransferase; Female; Humans; Immunohistochemistry; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Phosphoserine; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinolones; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Biological characterization of a novel antitumor quinolone.
Topics: Animals; Antineoplastic Agents; Bone Marrow; DNA, Neoplasm; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Prodrugs; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors.
Topics: Adolescent; Adult; Alcaligenes; Anti-Bacterial Agents; Bacteremia; Bone Marrow Transplantation; Catheterization; Female; Glucose; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Neutropenia; Pseudomonas putida; Quinolones; Retrospective Studies; Xanthomonas | 1996 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Neoplasms; Quinolones | 1999 |
In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones | 1990 |
In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
Topics: 4-Quinolones; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones | 1989 |
Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones; Staphylococcus; Streptococcus | 1988 |